>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

HIIQ +39%, ALDX +27.6%, FH +17.1%, (also FORM Holdings to acquire 100% of XpresSpa through a private placement of its common stock to Mistral Equity Parterns and other existing XpresSpa holders at $2.31/share or $1.73 mln), REN +12.7%, WAC +11.8%, ENDP +11%, CSLT +10.6%, WPRT +10.1%
AMPH +9.4%, VSLR +8.8%, CASC +8.3%, NVRO +7.5%, GIGA +6.5%, (also receives a $1.9 mln order for non-recurring engineering services associated with its Microsource business unit from an aerospace company), KNDI +6.5%, ATSG +6.3%, ATSG +6.3%, EGY +6.2%, EGY +6.2%, MIME +5.9%, HEAR+5.5%, (thinly traded), AMAG +5.4%, MCHP +5.3%, (also increased quarterly cash dividend to $0.36/share from $0.3595/share), LGIH +5.2%, BDSI +5%
CPE +4.7%, OPK +4.3%, IDI +4.1%, (also annouces Harry Jordan as COO), SIEN +4.1%, EGRX +3.9%, NILE +3.8%, WBMD +3.5%, WBMD +3.5%, INCY+3.5%, ZBRA +3.5%, MSTX +3.5%, ZLTQ +3.3%, FGEN +3.2%, OCUL +3.1%, AMID +3%
DQ +2.7%, IONS +2.6%, RSPP +2.4%, CECE +2.2%, IPHI +2%, IFF +1.7%, TWLO +1.5%, ELNK +1.3%, CLVS +1.3%, FSC +1.2%, EXC +1.1%, FSM +1%

M&A news: MWW +22.4% (to be acquired by Randstad Holding (RANJY) for $3.40 per share; also reported earnings), .

Other news:

ALDX +27.2% (reports 'positive' data from a clinical trial of NS2)
MESO +16.6% (thinly traded - Phase 2 trial results of Mesoblast's cell therapy show dose-related improvements in biologic refractory rheumatoid arthritis)
SPEX +14.9% (enters into a non-binding letter of intent to invest in DatChat in exchange for an equity security interest in DatChat)
VRX +6.4% (announces relaunch of generic Ofloxacin Otic solution, also reported earnings)
WPZ +4.7% (Williams and Williams Partners announced they have agreed to sell the companies' Canadian businesses to Inter Pipeline Ltd. for combined cash proceeds of $1.35 billion CAD)
CPS +3.9% (S&P announces Cooper-Standard Holdings will replace QLogic Corp. (QLGC) in the S&P SmallCap 600 after the close of trading on Wednesday August 10
PSTI +2.6% (announces that its critical limb ischemia program in the EU has been awarded an $8 mln grant)
AAL +2.6% (reports July and year-to-date 2016 traffic results)
NVO +1.7% (still checking)
BSX +0.5% (receives FDA approval for the EMBLEM MRI Subcutaneous Implantable Defibrillator System)

Analyst comments: